Ticagrelor Tablet 90 mg, 60 mg Suppliers & Bulk Manufacturers
Available Forms: Tablet
Available Strengths: 90 mg, 60 mg
Reference Brands: Brilinta(US & EU)
Category: Blood Disorder
Ticagrelor inhibits the P2Y12 receptor on platelets, preventing ADP-mediated activation and aggregation. It rapidly reduces clot formation, lowering the risk of heart attack and stroke in acute coronary syndrome. Benefits include fast action, reversible platelet inhibition, reduced cardiovascular events, and oral administration without the need for routine blood monitoring.
Product Description:
Ticagrelor, marketed as Brilinta, is approved in both the US by the FDA and in the EU via EMA for acute coronary syndrome and other cardiovascular indications. Regulatory approval requires a comprehensive dossier including clinical efficacy, safety data, manufacturing details, and pharmacovigilance plans. In the US, FDA review involves detailed submission of clinical trial results, while in the EU, EMA approval follows strict regional guidelines. For guidance on dossier preparation, regulatory pathways, and successful market entry strategies, visit PharmaTradz. Ensuring compliance with regional regulations is essential for the safe and effective commercialization of ticagrelor worldwide.
Ticagrelor Tablet — third party manufacturing & bulk supply
Ticagrelor Tablet 90 mg, 60 mg is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:
What to include when you enquire
- Destination market — determines which manufacturers hold the right site-level approvals
- First order quantity and estimated annual volume
- Whether you need a registration dossier or the product is already registered
- Packaging, labelling and language requirements
- Incoterms and required shelf life
Manufacturers of Ticagrelor Tablet listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding. Narcotic drugs and controlled substances are supplied strictly against valid import and export permits issued by the competent authorities.
Request a quote for Ticagrelor Tablet →The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Frequently Asked Questions
Ticagrelor is used to reduce the risk of stroke, heart attack, and other cardiovascular events in patients with acute coronary syndrome (ACS) or a history of myocardial infarction. It works by preventing platelets from clumping together and forming harmful blood clots.
Ticagrelor is a synthetic small-molecule antiplatelet drug belonging to the class of cyclopentyl-triazolo-pyrimidines. It reversibly inhibits the P2Y12 receptor on platelets, reducing platelet aggregation and thrombus formation.
Ticagrelor is marketed under the trade name Brilinta (USA/EU) and Brilique (UK/EU).
Ticagrelor is manufactured by AstraZeneca.
The complete generic name is ticagrelor.
The brand names include Brilinta (USA/EU) and Brilique (UK/EU).
Ticagrelor is manufactured in multiple countries including the USA, EU nations, and India, depending on the licensing and generic manufacturers.
Related Products
Anagrelide Hydrochloride
Strength:
0.5 mg
Form: Capsules
Reference Brands: Agrylin (USA)
View Details
Ferric Maltol
Strength:
30 mg
Form: Capsules
Reference Brands: Accrufer (USA), Feraccru (EU)
View Details
Lusutrombopag
Strength:
3 mg
Form: Tablets
Reference Brands: Mulpleta (USA), Mulpleo (EU)
View Details
Quick Response Guaranteed | Verified Suppliers
